Lv41
460 积分 2026-01-21 加入
Abstract 3389: Preclinical models for evaluating bispecific antibodies targeting PD-1 and VEGF
48分钟前
求助中
11 Preclinical models for investigating PD-1/VEGFA dual-targeting bispecific antibodies
58分钟前
求助中
Immune Reprogramming of Tumor Microenvironments by Cytotoxic Antibody–Drug Conjugate Payloads
5天前
已完结
Role of CD47 as a Marker of Self on Red Blood Cells
5天前
已完结
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management
7天前
已完结
Abstract 4427: Development of CLIO-8221: A HER2-targeted multi-payload ADC to address ADC resistance
1个月前
已完结
Abstract B123: Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects
1个月前
已完结
Unlike LGR4, LGR5 potentiates Wnt–β-catenin signaling without sequestering E3 ligases
2个月前
已完结
RSPO2-Based Peptibodies Conjugated with Pyrrolobenzodiazepine Dimer or Camptothecin Analogs Demonstrate Potent Antitumor Activity by Targeting the Three Receptors LGR4/5/6 in Colorectal Cancer and Neuroblastoma
2个月前
已完结
Discovery of the first dual PD-L1/JAK inhibitor with enhanced in vivo antitumor immunity
3个月前
已完结
皖公网安备34019202002308
